H. Lee Moffitt Cancer Center and Research Institute
With
National Comprehensive Cancer Network
AstraZeneca
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included.
Subjects must be able to read and speak English or Spanish at the 8th grade level.
You may not be if
Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.
Clareo Health | Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
